Freestone Capital Holdings’s PDL BioPharma, Inc. PDLI Stock Holding History

Freestone Capital Holdings’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-112	Closed	-$277	–	1287
2020 Q4	$277	Hold	112	–	–	﹤0.01%	1269
2020 Q3	$353	Buy	+112	New	+$358	﹤0.01%	1187
2013 Q4	–	Sell	-23,323	Closed	-$180K	–	431
2013 Q3	$180K	Buy	+23,323	New	+$187K	0.03%	318

Other funds holding PDLI

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Public Employees Retirement Association of Colorado Denver, Colorado $28.9B AUM 44.1% 1-Year Est. Return

Freestone Capital Holdings's PDLI Position: Q1 2021 in Review

Freestone Capital Holdings sold out of PDL BioPharma, Inc. (PDLI) in Q1 2021, closing a stake of 112 shares — an estimated $277 sold.

Freestone Capital Holdings first reported a position in PDLI in Q3 2013 and held it in 3 quarters. The position peaked at $180K in Q3 2013. 11 funds tracked by Wall St. Rank hold PDLI as of Q1 2021.

Freestone Capital Holdings reported no remaining PDL BioPharma, Inc. position as of Q1 2021 after selling out during the quarter.
Freestone Capital Holdings sold 112 PDL BioPharma, Inc. shares in Q1 2021, an estimated $277.
Freestone Capital Holdings first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 3 quarters.
Freestone Capital Holdings's PDL BioPharma, Inc. position peaked at $180K in Q3 2013.
11 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.